Display options
Cite
White JM, Schiffer JT, Bender Ignacio RA, et al. Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. mBio. 2021;12(6):e0334721doi: 10.1128/mbio.03347-21.
White, J. M., Schiffer, J. T., Bender Ignacio, R. A., Xu, S., Kainov, D., Ianevski, A., Aittokallio, T., Frieman, M., Olinger, G. G., & Polyak, S. J. (2021). Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. mBio, 12(6), e0334721. https://doi.org/10.1128/mbio.03347-21
White, Judith M, et al. "Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses." mBio vol. 12,6 (2021): e0334721. doi: https://doi.org/10.1128/mbio.03347-21
White JM, Schiffer JT, Bender Ignacio RA, Xu S, Kainov D, Ianevski A, Aittokallio T, Frieman M, Olinger GG, Polyak SJ. Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. mBio. 2021 Dec 21;12(6):e0334721. doi: 10.1128/mbio.03347-21. Epub 2021 Dec 21. PMID: 34933447.
Copy Download .nbib Format: NLM
Share it on

mBio. 2021 Dec 21;12(6):e0334721. doi: 10.1128/mbio.03347-21. Epub 2021 Dec 21.

Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses.

mBio

Judith M White, Joshua T Schiffer, Rachel A Bender Ignacio, Shuang Xu, Denis Kainov, Aleksandr Ianevski, Tero Aittokallio, Matthew Frieman, Gene G Olinger, Stephen J Polyak

Affiliations

  1. University of Virginiagrid.27755.32, Department of Cell Biology, Charlottesville, Virginia, USA.
  2. University of Virginiagrid.27755.32, Department of Microbiology, Charlottesville, Virginia, USA.
  3. University of Washington, Division of Allergy and Infectious Diseases, Seattle, Washington, USA.
  4. Fred Hutchinson Cancer Research Center, Vaccine and Infectious Diseases Division, Seattle, Washington, USA.
  5. Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
  6. Institute of Technology, University of Tartu, Tartu, Estonia.
  7. Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland.
  8. Oslo Centre for Biostatistics and Epidemiology (OCBE), University of Oslo, Oslo, Norway.
  9. Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  10. Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  11. MRIGlobal, Gaithersburg, Maryland, USA.
  12. Virology Division, Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
  13. Department of Global Health, University of Washington, Seattle, Washington, USA.
  14. Department of Microbiology, University of Washington, Seattle, Washington, USA.

PMID: 34933447 DOI: 10.1128/mbio.03347-21

Abstract

The world was unprepared for coronavirus disease 2019 (COVID-19) and remains ill-equipped for future pandemics. While unprecedented strides have been made developing vaccines and treatments for COVID-19, there remains a need for highly effective and widely available regimens for ambulatory use for novel coronaviruses and other viral pathogens. We posit that a priority is to develop pan-family drug cocktails to enhance potency, limit toxicity, and avoid drug resistance. We urge cocktail development for all viruses with pandemic potential both in the short term (<1 to 2 years) and longer term with pairs of drugs in advanced clinical testing or repurposed agents approved for other indications. While significant efforts were launched against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),

Keywords: COVID-19; Ebola virus; SARS-CoV-2; antiviral drugs; category A-C pathogens; countermeasures; drug synergy; early treatment; model-driven approach; pandemic preparedness; prophylaxis; viral pandemic

Publication Types

Grant support